论文部分内容阅读
青蒿素是我国学者从黄花蒿(Atr-emisia annua L.)中分离的一个抗疟新药,具有过氧基团的倍半帖内酯新型结构。和目前临床应用的其它抗疟药比,青蒿素具有速效、低毒的特点,特别是在救治脑型疟和抗氯喹恶性疟方面已达到国际先进水平。但它还存在口服剂量大、复发率高、溶解度小等问题。我们和桂林制药厂协作,对青蒿素进行结构改造的研究,所得衍生物之一青蒿醚(还原青蒿素-12-β甲基醚),经动物实验与临床试用结果,剂量比青蒿素小,疗效亦有所提高。制成的口服片,由于剂量小
Artemisinin is a new anti-malarial drug isolated from Artemisia annua L. by Chinese scholars. It has a new structure of sesquiterpene lactone. Compared with other antimalarial drugs currently used clinically, artemisinin has the characteristics of quick-acting and low-toxicity, and has reached international advanced level in the treatment of cerebral malaria and anti-chloroquine falciparum malaria. However, it also has problems such as large oral dose, high recurrence rate, and low solubility. We have collaborated with Guilin Pharmaceutical Factory to study the structural modification of artemisinin. One of the obtained derivatives is artemisinin (reduced artemisinin-12-β methyl ether). The results of animal experiments and clinical trials indicate that the dose is higher than Artemisia annua. Small, the efficacy has also improved. Made oral tablets due to small doses